Vetter becomes a member of the Association of Research-Based Pharmaceutical Companies (vfa)

Vetter is a strong partner for research-based pharmaceutical companies in the development, manufacturing, and packaging of complex injectable medications. © Vetter Pharma International GmbH

Vetter is a strong partner for innovative pharmaceutical companies in the development, manufacturing, and packaging of complex injectable medicines. © Vetter Pharma International GmbH

– Association enables Vetter to have extraordinary membership
– vfa recognizes the importance of pharmaceutical service providers in drug development and production
– Vetter takes on a role in important vfa committees

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has joined the Association of Research-Based Pharmaceutical Companies (vfa) as an extraordinary member. With this special membership, the vfa acknowledges the essential importance of pharmaceutical service providers in the field of complex injectable medications. Vetter supports research-based pharmaceutical companies worldwide in successfully bringing their products into clinical phases and subsequently to the market, as well as establishing them there. This begins with the joint development of patient-friendly delivery systems and extends to innovative, flexible filling processes as well as extensive assembly and packaging services.

Managing Director Peter Sölkner expresses pride: “For us, it is a great recognition that the vfa has invited us to collaborate. The association is the most important platform for pharmaceutical companies active in Germany to advance and support the strategic development of the industry and the location. Here, we can now also contribute our perspective. As a globally active pharmaceutical service provider with a production focus in Germany, we play an important role as a partner for small and large companies in the industry.”

Han Steutel, President of the Association of Research-Based Pharmaceutical Companies (vfa): “The manufacturing of injectable medications is an indispensable part of the innovative pharma and biotech industry. We are pleased that Vetter, a globally leading company in this field, is a member of the vfa.”

Engagement in vfa committee work

The substantive work within the association is carried out in thematically focused committees and working groups. Managing Director Peter Sölkner will represent Vetter on the Committee for Economic and Location Policy. Dr. Claus Feußner, Senior Vice President Development Service, has been appointed to the Research and Development Committee. Other Vetter experts participate in the working groups for Regulatory Affairs, Production, Innovation, and Communication.

With its membership in the vfa, the pharmaceutical service provider is additionally a member of the Chemical Industry Association (VCI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), which are committed at the EU level to strengthening and further developing member countries as research and production locations.

About the vfa

The vfa represents, with its current 48 member companies, more than two-thirds of the entire German pharmaceutical market. The companies employ around 94,000 people in Germany. More than 20,000 of them are involved in the research and development of medicines. In Germany alone, research-based pharmaceutical companies invest €8.7 billion annually in drug research for new and better medications.